Scilex Holding Company (SCLX) is a biopharmaceutical company based in Palo Alto, California, focused on the development and commercialization of non-opioid pain management products. The company aims to become a leader in this sector, with a commitment to ethical practices and improving quality of life through innovative therapies. Its lead product, ZTlido (lidocaine topical system), is FDA-approved for treating post-herpetic neuralgia, and the company has expanded its portfolio with additional FDA-approved products like ELYXYB and Gloperba.
Scilex Holding operates primarily through its subsidiary, Scilex Pharmaceuticals, which focuses on non-opioid pain management products. Additionally, Scilex has announced a merger involving another subsidiary, Semnur Pharmaceuticals, which is set to create a publicly traded biopharma company.